Angiogenesis in multiple myeloma

European Journal of Cancer

Volumn 42, Issue 11, 2006, Pages 1581-1590

  Jakob, Christian ^a   Sterz, Jan ^a   Zavrski, Ivana ^a   Heider, Ulrike ^a   Kleeberg, Lorenz ^a   Fleissner, Claudia ^a   Kaiser, Martin ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; bFGF; Bone marrow; Cytokines; Endothelial cells; HGF; Microenvironment; Multiple myeloma; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; OSTEOPONTIN; SCATTER FACTOR; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL FUNCTION; CELL GROWTH; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG MEGADOSE; ENDOTHELIUM CELL; EVIDENCE BASED MEDICINE; HUMAN; HYPOTHESIS; MICROENVIRONMENT; MICROVASCULATURE; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANGIOGENIC PROTEINS; BONE MARROW; CYTOKINES; HUMANS; MICROCIRCULATION; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33746332658     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.02.017     Document Type: Article

References (112)

1. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
3. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
4. Bergers G., and Benjamin L.E. Tumourigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
5. Folkman J. What is the evidence that tumours are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
6. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumour angiogenesis and metastasis: correlation with invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
7. Folkman J., and Shing Y. Angiogenesis. J Biol Chem 267 (1992) 10931-10934
8. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 86 (1996) 353-364
9. Kerbel R.S. Tumour angiogenesis: past, present and the near future. Carcinogenesis 21 (2000) 505-515
10. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumour growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
11. Podar K., and Anderson K.C. The pathophysiologic role of VEGF in haematologic malignancies: therapeutic implications. Blood 105 (2005) 1383-1395
12. Ray J.M., and Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7 (1994) 2062-7202
13. Hayes A.J., Huang W.Q., Mallah J., et al. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 58 (1999) 224-237
14. Hussong J.W., Rodgers G.M., and Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95 (2000) 309-313
15. Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96 (2000) 2240-2245
16. Perez-Atayde A., Sallan S.E., Tedrow U., et al. Spectrum of tumour angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150 (1997) 815-821
17. Kini A.R., Kay N.E., and Peterson L.C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 14 (2000) 1414-1418
18. Bertolini F., Paolucci M., Peccatori F., et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 106 (1999) 504-509
19. Vacca A., Ribatti D., Roccaro A.M., Frigeri A., and Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol 28 (2001) 543-550
20. Sezer O., Jakob C., and Niemoller K. Angiogenesis in cancer. J Clin Oncol 19 (2001) 3299-3301
21. Molina J.R., and Rajkumar S.V. Bone marrow angiogenesis in multiple myeloma: closing in on the loop. Haematologica 88 (2003) 122-124
22. Giuliani N., Colla S., and Rizzoli V. Angiogenic switch in multiple myeloma. Haematology 9 (2004) 377-381
23. Rajkumar S.V., Leong T., Roche P.C., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6 (2000) 3111-3116
24. Sezer O., Niemöller K., Jakob C., et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 79 (2000) 574-577
25. Singhal S., Mehta J., Desikan R., et al. Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
26. Nanda A., and St Croix B. Tumour endothelial markers: new targets for cancer therapy. Curr Opin Oncol 16 (2004) 44-49
27. Morgan G.J., and Davies F.E. Evolving treatment strategies for myeloma. Br J Cancer 92 (2005) 217-221
28. Uzzan B., Nicolas P., Cucherat M., and Perret G.Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64 (2004) 2941-2955
29. Galindo-Gallego M., Fernandez-Acenero M.J., Sanz-Ortega J., Aljama A., and Lopez-Elzaurdia C. Prognostic significance of microvascular counts in rectal carcinoma. Pathol Res Pract 196 (2000) 607-612
30. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
31. Graham C.H., Rivers J., Kerbel R.S., Stankiewicz K.S., and White W.L. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol 145 (1994) 510-514
32. Pruneri G., Bertolini F., Soligo D., et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 81 (1999) 1398-1401
33. Vermeulen P.B., Gasparini G., Fox S.B., et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A (1996) 2474-2484
34. Hasan J., Byers R., and Jayson G.C. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86 (2002) 1566-1577
35. Weidner N. Current pathologic methods for measuring intratumoural microvessel density within breast carcinoma and other solid tumours. Breast Cancer Res Treat 36 (1995) 169-180
36. Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87 (1994) 503-508
37. Schreiber S., Ackermann J., Obermair A., et al. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br J Haematol 110 (2000) 605-609
38. Rajkumar S.V., Mesa R.A., Fonseca R., et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary vamyloidosis. Clin Cancer Res 8 (2002) 2210-2216
39. Pruneri G., Ponzoni M., Ferreri A.J., et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118 (2002) 817-820
40. Alexandrakis M.G., Passam F.J., Ganotakis E., et al. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin Chem Lab Med 42 (2004) 1122-1126
41. Xu J.L., Lai R., Kinoshita T., Nakashima N., and Nagasaka T. Proliferation, apoptosis, and intratumoural vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 55 (2002) 530-534
42. Vacca A., Ribatti D., Roccaro A.M., et al. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol 106 (2001) 162-169
43. Niemöller K., Jakob C., Heider U., Zavrski I., Eucker J., Kaufmann O., et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 129 (2003) 234-238
44. Munshi N.C., and Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 28 (2001) 565-569
45. Kumar S., Ghellal A., Li C., et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumour prognosis. Cancer Res 59 (1999) 856-861
46. Kumar S., Gertz M.A., Dispenzieri A., et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 34 (2004) 235-239
47. Sezer O., Niemoller K., Jakob C., et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Ann Hematol 80 (2001) 598-601
48. Kumar S., Witzig T.E., Greipp P.R., and Rajkumar S.V. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. Br J Haematol 122 (2003) 272-274
49. Bataille R., Boccadoro M., Klein B., Durie B., and Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80 (1992) 733-737
50. Sezer O., Niemoller K., Kaufmann O., et al. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 66 (2001) 238-244
51. Kumar S., Fonseca R., Dispenzieri A., et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 119 (2002) 665-671
52. Kumar S., Witzig T.E., Dispenzieri A., et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18 (2004) 624-627
53. Hlatky L., Hahnfeldt P., and Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94 (2002) 883-893
54. De Raeve H.R., and Vanderkerken K. The role of the bone marrow microenvironment in multiple myeloma. Histol Histopathol 20 (2005) 1227-1250
55. Vacca A., Ribatti D., Presta M., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 (1999) 3064-3073
56. Kumar S., Witzig T.E., Timm M., et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favouring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 104 (2004) 1159-1165
57. Ria R., Roccaro A.M., Merchionne F., et al. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 17 (2003) 1961-1966
58. Kumar S., Witzig T.E., Timm M., et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 17 (2003) 2025-2031
59. Bellamy W.T., Richter L., Frutiger Y., and Grogan T.M. Expression of vascular endothelial growth factor and its receptors in haematopoietic malignancies. Cancer Res 59 (1999) 728-733
60. Dankbar B., Padro T., Leo R., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumour-stromal cell interactions in multiple myeloma. Blood 95 (2000) 2630-2636
61. Giuliani N., Colla S., Morandi F., et al. Angiogenic switch in multiple myeloma patients. Blood 102 (2003) 441a
62. Schweigerer L., Neufeld G., Friedman J., et al. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325 (1987) 257-259
63. Bisping G., Leo R., Wenning D., et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101 (2003) 2775-2783
64. Dhodapkar M.V., Abe E., Theus A., et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumour cell survival, growth, and bone cell differentiation. Blood 91 (1998) 2679-2688
65. Sanderson R.D., Lalor P., and Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1 (1989) 27-35
66. Witzig T., Kimlinger T., Stenson M., and Thereneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 31 (1998) 167-175
67. Bussolino F., Di Renzo M.F., Ziche M., et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119 (1992) 629-641
68. Borset M., Lien E., Espevik T., et al. Concomitant expression of hepatocyte growth factor and the receptor c-Met in human myeloma cell lines. J Biol Chem 271 (1996) 24655-24661
69. Vacca A., Ria R., Ribatti D., et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumour angiogenesis and growth in multiple myeloma. Haematologica 88 (2003) 176-185
70. Giuliani N., Colla S., Lazzaretti M., et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102 (2003) 638-645
71. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumours mediated by angiopoietins and VEGF. Science 284 5422 (1999) 1994-1998
72. Tsigkos S., Koutsilieris M., and Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 12 (2003) 933-941
73. Uneda S., Matsuno F., Sonoki T., et al. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica 88 (2003) 113-115
74. Hirama M., Takahashi F., Takahashi K., et al. Osteopontin overproduced by tumour cells acts as a potent angiogenic factor contributing to tumour growth. Cancer Lett 198 (2003) 107-117
75. Cheriyath V., and Hussein M.A. Osteopontin, angiogenesis and multiple myeloma. Leukemia 19 (2005) 2203-2205
76. Saeki Y., Mima T., Ishii T., et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 123 (2003) 263-270
77. Colla S., Morandi F., Lazzaretti M., et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 19 (2005) 2166-2176
78. Barille S., Akhoundi C., Collette M., et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90 (1997) 1649-1655
79. Curran S., and Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 189 3 (1999) 300-308
80. Hamano Y., Zeisberg M., Sugimoto H., et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3 (2003) 589-601
81. Vande Broek I., Asosingh K., Allegaert V., Leleu X., Facon T., Vanderkerken K., et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18 (2004) 976-982
82. Gupta D., Treon S.P., and Shima Y. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 (2001) 1950-1961
83. Chauhan D., Uchiyama H., Akbarali Y., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87 (1996) 1104-1112
84. Kaigler D., Krebsbach P.H., Polverini P.J., and Mooney D.J. Role of vascular endothelial growth factor in bone marrow stromal cell modulation of endothelial cells. Tissue Eng 9 (2003) 95-103
85. De Raeve H., Van Marck E., Van Camp B., and Vanderkerken K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol 19 (2004) 935-950
86. Dominici M., Campioni D., Lanza F., et al. Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features. Leukemia 15 (2001) 171-176
87. Zhang H., Vakil V., Braunstein M., et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105 (2005) 3286-3294
88. Vacca A., Ria R., Semeraro F., et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 102 (2003) 3340-3348
89. Vacca A., Scavelli C., Montefusco V., et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23 (2005) 5334-5346
90. Pellegrino A., Ria R., Di Pietro G., et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 129 (2005) 248-256
91. Moller C., Stromberg T., Juremalm M., Nilsson K., and Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17 (2003) 203-210
92. Vande Broek I., Asosingh K., Vanderkerken K., Straetmans N., Van Camp B., and Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 88 (2003) 855-862
93. Sezer O. Chemokine receptor expression in multiple myeloma. Haematologica 91 (2006) 148
94. Asosingh K., Gunthert U., De Raeve H., et al. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 61 (2001) 2862-2865
95. Streubel B., Chott A., Huber D., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351 (2004) 250-259
96. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumour angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
97. Salven P., Teerenhovi L., and Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90 (1997) 3167-3172
98. Borset M., Hjorth-Hansen H., Seidel C., Sundan A., and Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88 (1996) 3998-4004
99. Seidel C., Borset M., Turesson I., et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 91 (1998) 806-812
100. Iwasaki T., Hamano T., Ogata A., et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 116 (2002) 796-802
101. Andersen N.F., Standal T., Nielsen J.L., et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 128 (2005) 210-217
102. Sezer O., Jakob C., Eucker J., et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 66 (2001) 83-88
103. Banks R.E., Forbes M.A., Kinsey S.E., et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77 (1998) 956-964
104. Sato N., Hattori Y., Wenlin D., et al. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity. Jpn J Cancer Res 93 (2002) 459-466
105. Di Raimondo F., Azzaro M.P., Palumbo G., et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85 (2000) 800-805
106. Kyrtsonis M.C., Vassilakopoulos T.P., Siakantaris M.P., et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 72 (2004) 252-258
107. Seidel C., Sundan A., Hjorth M., et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95 (2000) 388-392
108. Seidel C., Lenhoff S., Brabrand S., et al. For the Nordic Myeloma Study Group. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 119 (2002) 672-676
109. Jakob C., Fleissner C., Zavrski I., et al. Circulating hepatocyte growth factor levels in multiple myeloma. Br J Haematol 121 (2003) 532
110. Dmoszynska A., Bojarska-Junak A., Domanski D., et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 43 (2002) 401-406
111. Neben K., Moehler T., Egerer G., et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res. 7 (2001) 2675-2681
112. Hatjiharissi E., Terpos E., Papaioannou M., et al. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Haematol Oncol 22 (2004) 159-168